Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189598 | 0.87 | — | — | |
| SCHEMBL4887775 | 0.83 | — | — | |
| SCHEMBL8941008 | 0.78 | PKM (0.44) | PKM | |
| SCHEMBL11405480 | 0.78 | PKM (0.44) | PKM | |
| SCHEMBL22660504 | 0.78 | — | — | |
| SCHEMBL14859331 | 0.77 | — | — | |
| SCHEMBL14403170 | 0.76 | — | — | |
| SCHEMBL9905932 | 0.73 | — | — | |
| SCHEMBL4055534 | 0.72 | EPHX2 (0.32) | — | |
| SCHEMBL732916 | 0.70 | GRIN1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116046926-B | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-116143587-A | Synthesis method of memantine hydrochloride impurity standard substance 3,5, 7-trimethyl adamantanol | 合肥久诺医药科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-116046926-A | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-1999100-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-12-10 | — | — | EP | claimed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| CN-116046926-B | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-116143587-A | Synthesis method of memantine hydrochloride impurity standard substance 3,5, 7-trimethyl adamantanol | 合肥久诺医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116143587-A | Synthesis method of memantine hydrochloride impurity standard substance 3,5, 7-trimethyl adamantanol | 合肥久诺医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116046926-A | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8796491-B2 | Process for manufacturing adamantane derivatives with high yield | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-08-05 | — | — | US | disclosed |
| EP-1989177-B1 | AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME | UNIV GIESSEN JUSTUS LIEBIG (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-1989177-A1 | AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME | Justus-Liebig-Universität Giessen (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007101535-A1 | AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | PNMT, PSEN2, CHRNA5 | PKM 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.